Cargando…

Ochratoxin A Induces Steatosis via PPARγ-CD36 Axis

Ochratoxin A(OTA) is considered to be one of the most important contaminants of food and feed worldwide. The liver is one of key target organs for OTA to exert its toxic effects. Due to current lifestyle and diet, nonalcoholic fatty liver disease (NAFLD) has been the most common liver disease. To ex...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Qian-Wen, Ding, Xu-Fen, Cao, Hui-Jun, Ni, Qian-Zhi, Zhu, Bing, Ma, Ning, Zhang, Feng-Kun, Wang, Yi-Kang, Xu, Sheng, Chen, Tian-Wei, Xia, Ji, Qiu, Xiao-Song, Yu, Dian-Zhen, Xie, Dong, Li, Jing-Jing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8620754/ https://www.ncbi.nlm.nih.gov/pubmed/34822586 http://dx.doi.org/10.3390/toxins13110802

Ejemplares similares

PEGylated Curcumin Derivative Attenuates Hepatic Steatosis via CREB/PPAR-γ/CD36 Pathway
por: Liu, Yu, et al.
Publicado: (2017)

The CD36-PPARγ Pathway in Metabolic Disorders
por: Maréchal, Loïze, et al.
Publicado: (2018)

WISP1 alleviates lipid deposition in macrophages via the PPARγ/CD36 pathway in the plaque formation of atherosclerosis
por: Liu, Dian, et al.
Publicado: (2020)

Hepatic DKK1-driven steatosis is CD36 dependent
por: Yang, Zhen, et al.
Publicado: (2022)

Non-proteolytic ubiquitin modification of PPARγ by Smurf1 protects the liver from steatosis
por: Zhu, Kun, et al.
Publicado: (2018)

Fingolimod treatment modulates PPARγ and CD36 gene expression in women with multiple sclerosis
por: Ferret-Sena, Véronique, et al.
Publicado: (2022)

CD36/Sirtuin 1 Axis Impairment Contributes to Hepatic Steatosis in ACE2-Deficient Mice
por: Nunes-Souza, Valéria, et al.
Publicado: (2016)

Porphyromonas gingivalis exacerbates the progression of fatty liver disease via CD36-PPARγ pathway
por: Ahn, Ji-Su, et al.
Publicado: (2021)

Overexpression CPT1A reduces lipid accumulation via PPARα/CD36 axis to suppress the cell proliferation in ccRCC: CPT1A inhibits ccRCC cell proliferation via PPARα/CD36 axis
por: Yang, Hui, et al.
Publicado: (2021)

Nrf2, a PPARγ Alternative Pathway to Promote CD36 Expression on Inflammatory Macrophages: Implication for Malaria
por: Olagnier, David, et al.
Publicado: (2011)

Scaffold-Based Pan-Agonist Design for the PPARα, PPARβ and PPARγ Receptors
por: Zhang, Li-Song, et al.
Publicado: (2012)

Alisol B Alleviates Hepatocyte Lipid Accumulation and Lipotoxicity via Regulating RARα-PPARγ-CD36 Cascade and Attenuates Non-Alcoholic Steatohepatitis in Mice
por: Zhao, Zhuohui, et al.
Publicado: (2022)

The role of CD36-Fabp4-PPARγ in skeletal muscle involves insulin resistance in intrauterine growth retardation mice with catch-up growth
por: Liu, Jing, et al.
Publicado: (2022)

Dnmt1/Tet2-mediated changes in Cmip methylation regulate the development of nonalcoholic fatty liver disease by controlling the Gbp2-Pparγ-CD36 axis
por: Lee, Jangho, et al.
Publicado: (2023)

Protopanaxatriol, a novel PPARγ antagonist from Panax ginseng, alleviates steatosis in mice
por: Zhang, Yu, et al.
Publicado: (2014)

Hepatocyte-specific Nrf2 deficiency mitigates high-fat diet-induced hepatic steatosis: Involvement of reduced PPARγ expression
por: Li, Lu, et al.
Publicado: (2019)

Quercetin protects against atherosclerosis by regulating the expression of PCSK9, CD36, PPARγ, LXRα and ABCA1
por: Jia, Qingling, et al.
Publicado: (2019)

PPDPF alleviates hepatic steatosis through inhibition of mTOR signaling
por: Ma, Ning, et al.
Publicado: (2021)

Cathelicidin suppresses lipid accumulation and hepatic steatosis by inhibition of the CD36 receptor
por: Tran, Deanna Hoang-Yen, et al.
Publicado: (2016)

Suppression of PPARγ-mediated monoacylglycerol O-acyltransferase 1 expression ameliorates alcoholic hepatic steatosis
por: Yu, Jung Hwan, et al.
Publicado: (2016)

Liver-Specific Deletion of Mouse CTCF Leads to Hepatic Steatosis via Augmented PPARγ Signaling
por: Choi, Yeeun, et al.
Publicado: (2021)

Flavonoid Extract from Propolis Provides Cardioprotection following Myocardial Infarction by Activating PPAR-γ
por: Wang, Qian, et al.
Publicado: (2022)

High-density Lipoprotein Increases the Uptake of Oxidized Low Density Lipoprotein via PPARγ/CD36 Pathway in Inflammatory Adipocytes
por: Zhong, Qiaoqing, et al.
Publicado: (2015)

An Erk/Cdk5 axis controls the diabetogenic actions of PPARγ
por: Banks, Alexander S., et al.
Publicado: (2014)

PPAR-γ Agonists As Antineoplastic Agents in Cancers with Dysregulated IGF Axis
por: Vella, Veronica, et al.
Publicado: (2017)

The Modulation of PPARγ1 and PPARγ2 mRNA Expression by Ciglitazone in CD3/CD28-Activated Naïve and Memory CD4+ T Cells
por: Norazmi, Mohd Nor, et al.
Publicado: (2012)

Amorfrutins Relieve Neuropathic Pain through the PPARγ/CCL2 Axis in CCI Rats
por: Gao, Pengfei, et al.
Publicado: (2021)

Apolipoprotein D Transgenic Mice Develop Hepatic Steatosis through Activation of PPARγ and Fatty Acid Uptake
por: Labrie, Marilyne, et al.
Publicado: (2015)

Altered FoxO1 and PPARγ interaction in age-related ER stress-induced hepatic steatosis
por: Kim, Dae Hyun, et al.
Publicado: (2019)

Tetrahydroxanthohumol, a xanthohumol derivative, attenuates high-fat diet-induced hepatic steatosis by antagonizing PPARγ
por: Zhang, Yang, et al.
Publicado: (2021)

Role of the adipose PPARγ-adiponectin axis in susceptibility to stress and depression/anxiety-related behaviors
por: Guo, M, et al.
Publicado: (2017)

The PPARγ Agonist Rosiglitazone Enhances the Radiosensitivity of Human Pancreatic Cancer Cells
por: Wang, Zhenyu, et al.
Publicado: (2020)

A PPARγ-dependent miR-424/503-CD40 axis regulates inflammation mediated angiogenesis
por: Lee, Aram, et al.
Publicado: (2017)

Endothelial Dec1-PPARγ Axis Impairs Proliferation and Apoptosis Homeostasis Under Hypoxia in Pulmonary Arterial Hypertension
por: Li, Xiaoming, et al.
Publicado: (2021)

STK38 is a PPARγ-interacting protein promoting adipogenesis
por: Qian, Kun, et al.
Publicado: (2021)

PPARγ Regulates Triclosan Induced Placental Dysfunction
por: Li, Jing, et al.
Publicado: (2021)

Molecular Determinants of Magnolol Targeting Both RXRα and PPARγ
por: Zhang, Haitao, et al.
Publicado: (2011)

Chiglitazar Preferentially Regulates Gene Expression via Configuration-Restricted Binding and Phosphorylation Inhibition of PPARγ
por: Pan, De-Si, et al.
Publicado: (2017)

The role and function of PPARγ in bladder cancer
por: Peng, Tianchen, et al.
Publicado: (2020)

Molecular Modelling Study of the PPARγ Receptor in Relation to the Mode of Action/Adverse Outcome Pathway Framework for Liver Steatosis
por: Tsakovska, Ivanka, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_a4e1gpao97cispg959hm7pk256